Skip to content

VEST Device to Enhance Safein Vein Patency

Mid Term Follow up of VEST Device to Enhance Safein Vein Patency: a Multicentric Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06500897
Enrollment
385
Registered
2024-07-15
Start date
2017-01-02
Completion date
2024-07-08
Last updated
2024-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Bypass

Keywords

Coronary Artery Bypass, Safein Vein, Mesh support

Brief summary

Purpose - Bypass grafting is the gold standard for severe coronary disease, yet most repeat revascularizations target previously grafted territories. External stenting of saphenous vein grafts, the most frequently used bypass conduit, has been shown to minimize disease markers. This study evaluates clinical outcomes of external stenting in real world routine practice. Methods - Three centers enrolled a prospective real-world cohort of external- stenting- enhanced CABG patients. All patients received an internal mammary artery graft to the left anterior descending artery and additional arterial and/or venous grafts. One or more venous grafts were externally stented. Choice of conduits, use of cardiopulmonary bypass, and vein harvesting technique were performed according to the routine practice of each surgeon. All patients were prescribed standard of care medication and were followed via on site visits or phone interviews for major adverse myocardial and cerebral effects.

Interventions

DEVICEVEST

External MEsh Support for safein vein

Sponsors

Cardiochirurgia E.H.
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* CABG with at least one VEST implant

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Re-rivascularizationUp to 7 yearsNumber of PCI or re-CABG performed, stratified by target site
MACCEUp to 7 yearsMajor adverse cardiac and cerebrovascular events

Countries

Austria, Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026